Clinical Trial Update: Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease [Phase 2]

View source ↗

Summary

A Phase 2 study of MT-1303 in moderate to severe Crohn's disease has completed. The trial reported safety and efficacy findings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• MT-1303

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED